Baidu
map

Ann Intern Med:全甲状腺切除术可改善桥本病与健康相关的生活质量和疲劳,而药物治疗却不行

2020-08-05 MedSci原创 MedSci原创

桥本病是一种慢性自身免疫性甲状腺炎。尽管有充分的激素替代,但部分患者仍有持续的症状,这可能是免疫性病理生理的结果。本研究旨在确定桥本甲状腺炎患者在接受医学治疗的同时,虽然甲状腺功能正常但仍有症状者接受

桥本病是一种慢性自身免疫性甲状腺炎。尽管有充分的激素替代,但部分患者仍有持续的症状,这可能是免疫性病理生理的结果。本研究旨在确定桥本甲状腺炎患者在接受医学治疗的同时,虽然甲状腺功能正常但仍有症状者接受甲状腺切除术是否能改善其症状。

 

采用随机试验设计,在挪威的二级保健医院进行,纳入了150名年龄在18岁至79岁的患者,尽管甲状腺功能正常,但仍存在桥本相关的持续症状,同时接受激素替代治疗且血清抗甲状腺过氧化物酶(anti-TPO)抗体滴度大于1000 IU/mL。

 

两组均行甲状腺全切除术或用激素替代治疗以确保甲状腺功能正常。主要结果是18个月时短表36健康调查(SF-36)的总体健康评分。次要结果是手术的不良反应、其他7个SF-36分项、疲劳问卷评分以及6、12和18个月的血清抗TPO抗体滴度。

 

结果显示,随访期间,只有手术组表现出改善:平均总体健康评分从38分增加到64分,18个月时组间差异为29分(95%CI,22-35分)。疲劳评分从23分降至14分,组间差异为9.3分(CI,7.4-11.2分)。慢性疲劳频率从82%降至35%,组间差异为39个百分点(CI,23-53个百分点)。中位血清抗TPO抗体滴度从2232下降到152 IU/mL,组间差异为1148 IU/mL(CI,1080~1304 IU/mL)。在多变量回归分析中,校正后的治疗效果仍与未校正的效果相似。

 

综上所述,该研究结果表明,全甲状腺切除术改善了与健康相关的生活质量和疲劳,而药物治疗却没有。这种改善,以及伴随着血清抗TPO抗体的消除,可能阐明了疾病机制。研究的局限性在于结果仅适用于桥本病患者的一个亚组,随访时间限于18个月。

 

原始出处:

 

Ivar GuldvogLaurens Cornelus Reitsma, et al., Thyroidectomy Versus Medical Management for Euthyroid Patients With Hashimoto Disease and Persisting Symptoms: A Randomized Trial. Ann Intern Med. 2019 Apr 2;170(7):453-464. doi: 10.7326/M18-0284. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1877317, encodeId=181a18e73173e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 15 19:45:19 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677282, encodeId=cf4d16e7282d5, content=<a href='/topic/show?id=56b36239208' target=_blank style='color:#2F92EE;'>#桥本病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62392, encryptionId=56b36239208, topicName=桥本病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad7e27471083, createdName=zhishijing, createdTime=Thu Oct 08 04:45:19 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260919, encodeId=746b126091974, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 07:45:19 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610640, encodeId=339d16106405c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 07 07:45:19 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1877317, encodeId=181a18e73173e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 15 19:45:19 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677282, encodeId=cf4d16e7282d5, content=<a href='/topic/show?id=56b36239208' target=_blank style='color:#2F92EE;'>#桥本病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62392, encryptionId=56b36239208, topicName=桥本病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad7e27471083, createdName=zhishijing, createdTime=Thu Oct 08 04:45:19 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260919, encodeId=746b126091974, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 07:45:19 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610640, encodeId=339d16106405c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 07 07:45:19 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1877317, encodeId=181a18e73173e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 15 19:45:19 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677282, encodeId=cf4d16e7282d5, content=<a href='/topic/show?id=56b36239208' target=_blank style='color:#2F92EE;'>#桥本病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62392, encryptionId=56b36239208, topicName=桥本病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad7e27471083, createdName=zhishijing, createdTime=Thu Oct 08 04:45:19 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260919, encodeId=746b126091974, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 07:45:19 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610640, encodeId=339d16106405c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 07 07:45:19 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
    2020-08-07 tamgche
  4. [GetPortalCommentsPageByObjectIdResponse(id=1877317, encodeId=181a18e73173e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Dec 15 19:45:19 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677282, encodeId=cf4d16e7282d5, content=<a href='/topic/show?id=56b36239208' target=_blank style='color:#2F92EE;'>#桥本病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62392, encryptionId=56b36239208, topicName=桥本病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad7e27471083, createdName=zhishijing, createdTime=Thu Oct 08 04:45:19 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260919, encodeId=746b126091974, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Fri Aug 07 07:45:19 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610640, encodeId=339d16106405c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Aug 07 07:45:19 CST 2020, time=2020-08-07, status=1, ipAttribution=)]

相关资讯

解读桥本病(桥本氏甲状腺炎)

桥本氏甲状腺炎(Hashimoto’s thyroiditis,HT)亦称桥本病,是自身免疫性甲状腺炎,又称慢性淋巴性甲状腺炎。

Baidu
map
Baidu
map
Baidu
map